Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants by Dowrick, Christopher F et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Health Services Research
Open Access Research article
Considering the case for an antidepressant drug trial involving 
temporary deception: a qualitative enquiry of potential participants
Christopher F Dowrick*1, John G Hughes1, Julia J Hiscock2, 
Mark Wigglesworth3 and Thomas J Walley4
Address: 1Division of Primary Care, University of Liverpool, Whelan Building, Liverpool L69 3GB, UK, 2National Primary Care Research and 
Development Centre, 5th Floor, Williamson Building, University of Manchester, Oxford Road, M13 9PL, UK, 3Aintree Park Group Practice, 46 
Moss Lane, Orrell Park, Liverpool, L9 8AL, UK and 4Prescribing Research Group, Division of Biomedical Sciences, Pharmacology and Therapeutics, 
University of Liverpool, L69 3GB, UK
Email: Christopher F Dowrick* - cfd@liverpool.ac.uk; John G Hughes - John.Hughes@liverpool.ac.uk; 
Julia J Hiscock - Julia.hiscock@manchester.ac.uk; Mark Wigglesworth - wigglem@fsmail.net; Thomas J Walley - t.walley@liverpool.ac.uk
* Corresponding author    
Abstract
Background: Systematic reviews of randomised placebo controlled trials of antidepressant medication show small and
decreasing differences between pharmacological and placebo arms. In part this finding may relate to methodological
problems with conventional trial designs, including their assumption of additivity between drug and placebo trial arms.
Balanced placebo designs, which include elements of deception, may address the additivity question, but pose substantial
ethical and pragmatic problems. This study aimed to ascertain views of potential study participants of the ethics and
pragmatics of various balanced placebo designs, in order to inform the design of future antidepressant drug trials.
Methods: A qualitative approach was employed to explore the perspectives of general practitioners, psychiatrists, and
patients with experience of depression. The doctors were chosen via purposive sampling, while patients were recruited
through participating general practitioners. Three focus groups and 12 in-depth interviews were conducted. A vignette-
based topic guide invited views on three deceptive strategies: post hoc, authorised and minimised deception. The focus
groups and interviews were tape-recorded and transcribed. Transcripts were analysed thematically using Framework.
Results: Deception in non-research situations was typically perceived as acceptable within specific parameters. All
participants could see the potential utility of introducing deception into trial designs, however views on the acceptability
of deception within antidepressant drug trials varied substantially. Authorized deception was the most commonly
accepted strategy, though some thought this would reduce the effectiveness of the design because participants would
correctly guess the deceptive element. The major issues that affected views about the acceptability of deception studies
were the welfare and capacity of patients, practicalities of trial design, and the question of trust.
Conclusion: There is a trade-off between pragmatic and ethical responses to the question of whether, and under what
circumstances, elements of deception could be introduced into antidepressant drug trials. Ensuring adequate ethical
safeguards within balanced placebo designs is likely to diminish their ability to address the crucial issue of additivity. The
balanced placebo designs considered in this study are unlikely to be feasible in future trials of antidepressant medication.
However there remains an urgent need to improve the quality of antidepressant drug trials.
Published: 30 April 2007
BMC Health Services Research 2007, 7:64 doi:10.1186/1472-6963-7-64
Received: 27 November 2006
Accepted: 30 April 2007
This article is available from: http://www.biomedcentral.com/1472-6963/7/64
© 2007 Dowrick et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
Page 2 of 12
(page number not for citation purposes)
Background
Is antidepressant medication useful?
There is considerable debate concerning the utility of anti-
depressant medication in the treatment of depressive dis-
orders. The prevailing view amongst psychiatrists is that
antidepressant medication is of proven efficacy in reduc-
ing the severity and duration of major depression and
should therefore be used as its first line of treatment [1].
However systematic reviews of randomised double blind
placebo controlled trials of antidepressant medication
indicate that differences in outcome between drug and
placebo arms are often marginal, and may be exaggerated
by selective publication or even deliberate misrepresenta-
tion [2]. Consensus and editorial statements indicate an
awareness that this raises important and unresolved ques-
tions [3,4].
In a review of 75 placebo controlled trials of antidepres-
sant medication prescribed in outpatient settings, Walsh
et al concluded that the placebo response is 'variable, sub-
stantial and growing'. They calculated that about 30 per
cent of the patients who were assigned to placebo groups
in these trials showed clinically significant improvement,
with a range from 12.5 per cent to over 50 per cent. This
compared with an average response of 50 per cent to the
main active medication being tested in the trial [5].
Walsh et al report that the proportion of people respond-
ing to placebo, and also to active medication, has
increased at a rate of about seven per cent per decade. As
treatments for depression have become more widely avail-
able and socially acceptable, it has become easier to
recruit members of the general public to take part in clin-
ical trials, rather than relying on patients referred from
other clinicians. As a result, it is possible that clinically
important characteristics of patients taking part in treat-
ment studies may have altered. For example people com-
ing forward from the general public may have less chronic
types of depression, or experience fewer contributory life
difficulties, than those recruited through hospital clinics.
It is also possible that the increased social acceptability of
depression and its management have affected the beliefs
and expectation of both clinicians and patients taking part
in trials, which in turn may enhance placebo effects.
Kirsch et al analysed the antidepressant medication data
submitted to the United States' drug regulatory agency,
the Food and Drug Administration (FDA) [6]. This is a dif-
ferent database from that used by Walsh et al, which was
based on peer reviewed published trials. Here they exam-
ined the studies presented as evidence by pharmaceutical
companies to the United States government, on the basis
of which licences were granted to market particular anti-
depressant drugs. Using Hamilton's depression rating
scale as their benchmark, they found that the mean differ-
ences between responses to antidepressant drugs and pla-
cebo was only two points, within a range from 0 to 52
points. While this difference was statistically significant,
its relevance in terms of clinical practice is questionable.
Khan et al also used the FDA database to evaluate clinical
trial data from the nine antidepressants approved by the
FDA between 1985 and 2000 [7]. These trials comprised
10,030 depressed patients who participated in 52 clinical
trials evaluating 93 treatment arms. Less than half (48%,
45/93) of the antidepressant treatment arms showed
superiority to placebo.
In combination, these reports raise important methodo-
logical issues:
First, the average length of antidepressant drug trials has
increased significantly during the past twenty years,
though few continue beyond 12 weeks. This gives more
time for the cumulative effects of "best medical care" and
non-specific interventions which are inherent and inevita-
ble in clinical trials, and – importantly – provides a longer
period during which spontaneous recovery could be
observed [5].
Second, many drug trials now include a placebo 'run-in
period', which is designed to exclude those patients with
disorders which resolve spontaneously. This tends to
increase the apparent efficacy of antidepressant medica-
tion.
Third, there is debate over the use of active (i.e. designed
to mimic expected side effects of trial drug) or inert place-
bos, and the effect of this on the ability of doctors and
patients to guess which trial arm they are in. Correctly
guessing may have the effect of increasing observed differ-
ences between active and control arms [8], particularly in
milder disorders where patients' beliefs about the efficacy
or otherwise of medication affect their response to it [9].
Finally, we have the fundamental problem that clinical tri-
als are based on the assumption of additivity. That is, the
drug is deemed effective only if the response to it is signif-
icantly greater than the response to placebo, and the mag-
nitude of the drug effect is assumed to be the difference
between the response to drug and the placebo. However,
this assumption is problematic [10].
The problem of additivity
Clinical trials of antidepressant medication are based on
the method of residues: the assumption that the magni-
tude of the drug effect is the difference between response
to drug and placebo. However this assumption is simplis-
tic. The placebo effect is not simply additive, but can beBMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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synergistic or even antagonistic, with a complex web of
intricate variables influencing the healing response [11].
Alcohol and stimulant drugs, for example, produce at
least some drug and placebo effects that are not additive.
Placebo alcohol produces effects that are not observed
when alcohol is administered surreptitiously, and alcohol
produces effects that are not duplicated by placebo alco-
hol. The placebo and pharmacological effects of caffeine
are additive for feelings of alertness but not for feelings of
tension, and similarly mixed results have been reported
for other stimulants [12].
If antidepressant drug effects and antidepressant placebo
effects are not additive, the ameliorating effects of antide-
pressants might be obtained even if patients did not know
the drug was being administered. If that is the case, then
antidepressant drugs have substantial pharmacologic
effects that are duplicated or masked by placebo. In this
case, conventional clinical trials are inappropriate for test-
ing the effects of these drugs, as they may result in the
rejection of effective medications. Conversely, if drug and
placebo effects of antidepressant medication are additive,
then the data produced by Kirsch and others indicate that
those effects are small, at best, and of questionable clinical
efficacy. Finally, it is conceivable that the effects are par-
tially additive, with the true drug effect being somewhere
in between these extremes.
We do not know which of these models is most accurate,
because the assumption of additivity has never been
tested with antidepressant medication.
Balanced placebo designs
One method of testing the additivity issue is the use of the
balanced placebo design [10]. In this design participants are
recruited for a study in which active drug or placebo will
be administered. Half of the participants are told they are
receiving active drug and half are told they are receiving
placebo. In other words, they are apparently being
unblinded at the start of the trial. In fact half of the partic-
ipants are given an active drug and half are not, but with
a crucial difference. Depending on assignment, partici-
pants will have one of four possible interventions: told
they are getting the drug and do in fact receive it; told they
are getting drug but in fact receive placebo; told they are
getting placebo but in fact receive drug; and told they are
getting placebo and in fact receive placebo. This permits
independent and combined assessment of drug and pla-
cebo effects. Thus, half of the participants are misin-
formed about what they will receive and are debriefed
post-hoc, after participation in the trial.
The balanced placebo design is useful because it provides
a direct assessment of the drug effect, independent of
expectancy. It has most commonly been deployed to test
the role of expectancy on the effects of alcohol and caf-
feine consumption, usually with healthy volunteer sam-
ples [13,14]. It has the advantage that the told drug/get
drug non-deceptive arm has more external valid than the
double blind administration in conventional randomised
trials, because they more accurately represent what hap-
pens in clinical practice. It has not yet been used in clinical
trials of antidepressant medication, because of the ethical
issues involved with temporary deception. However it is
necessary to consider the merits of adopting an approach
along these lines, if the question of the actual efficacy or
otherwise of antidepressant medication is ever to be
resolved.
Ethics and pragmatics
The ethical problems with conducting a trial involving an
element of deception are legion. Valid consent is estab-
lished as a basic tenet of health care research, and a design
involving temporary deception appears to fly in the face of
this fundamental ethical principle. In order for consent to
be valid, potential participants need to be able to make a
decision in the light of all the relevant information about
the proposed research procedure, including information
about the nature, purpose, major risks and benefits of the
procedure. Failure to obtain valid consent entails a lack of
respect for the autonomy of persons, and is also likely to
undermine patient's trust in health care professionals and
medical research, a result which would clearly not be con-
ducive to the long term interest of patients. Moreover, fail-
ure to be properly informed is likely to result in the harm
of potential participants and others, either in terms of the
distress that subsequent knowledge of deception may
cause participants and others, and/or in terms of the sig-
nificant risks to which deception may expose participants
and others: for example if a participant decided to misuse
a drug substance, believing it to be a placebo.
There are also many possible obstacles at the clinical level.
Doctors might refuse to support such a trial or recruit
patients for it. They might be convinced of the value of
antidepressants, concerned by the amount of time it
would take them to explain the trial's rationale to their
patients, or worried by the prospect of creating such a high
degree of uncertainty at a very delicate time in their
patients' lives. They might also worry that this would have
a damaging effect on the essential sense of trust that exists
between themselves and their patients. The general public
might consider all of the above reasons as valid, and won-
der why there are still so many unanswered questions
about a treatment approach that they had previously
taken for granted.BMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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Two approaches have been suggested to minimize such
difficulties: pre-consent (including authorized deception
and generic pre-consent) and minimised deception
Pre-consent
The principle of authorized deception has been advocated
by Wendler and Miller [15]. They propose that subjects
can be informed that a particular study involves decep-
tion, and asked to consent to its use, without being
informed of the nature of the deception. Such a design has
been used, for example, in the study of outreach stroke
care [16].
This may offer a useful way forward. Although potential
participants will be unaware of the nature of the decep-
tion, their autonomy would still seem to be respected
because they will have consented to the deception Of
course, participants would be very interested in trying to
second guess which aspects of the study were being mis-
described, and this is likely to have unpredictable influ-
ences on the main question. A further issue is the extent to
which the risks and benefits of a study can be determined
without recourse to the potential participants' own views
on the study – the point being that different aspects of a
study may pose different ethical, religious or personal
concerns for different participants. There may be no satis-
factory way of checking this without first discussing the
details of the study with potential participants. Finally,
there is also the possibility that knowledge of deception
taking place – even if consented to – might still cause par-
ticipants some degree of anxiety, a possibility that ought
to be avoided especially given the types of participants
that would be recruited. However if the above concerns
can be met, then authorized deception may represent a
more acceptable study design to those participating in
such a trial.
Generic pre-consent
Patients who are likely to be offered antidepressants – i.e.
those who have had at least one previous treated episode
of major depression – could be pre-consented to take part
in a balanced placebo trial in the future. This might be eth-
ically more acceptable to potential participants, but might
affect the placebo arm by introducing a high (and
unwanted) level of uncertainty in the minds of study par-
ticipants. Moreover, consent is generally recognized as a
process, not a one-off event. Potential participants may
change their minds over the course of time for a variety of
reasons, and therefore it cannot be assumed that an earlier
act of consent will necessarily be valid at a later date.
Minimised deception
The degree of deception could be reduced by randomizing
two-thirds/one third rather than half/half, and introduc-
ing the word 'probably'. Instead of patients being told
"you will receive a placebo", they could be told "it is prob-
able that you will receive a placebo", and the randomisa-
tion would then be two-thirds in favour of a placebo. This
means that the information given to patients at the time
they consented was correct, in that the majority of those
told they would get a placebo, would in fact get a placebo.
The statement that "it is probable that you will receive a
placebo" is not by any means as definitive as "you will get
a placebo" but it does not deceive the patient, since it is
formally accurate.
Study questions
To clarify these issues, prior to deciding whether a trial
involving temporary deception could be feasible or ethi-
cally permissible, it would be helpful to gauge opinion
amongst those groups of people who would be involved
in such a trial: people with experience of depression, and
(as most UK antidepressant trials recruit patients through
them) general practitioners and psychiatrists. If it could be
shown that sufficient of these groups were convinced of
the validity and value of such a study, this might give
added weight to the justification for such a trial.
We therefore sought to gather opinion from potential par-
ticipants on two key questions:
1. Would a balanced placebo study of antidepressants be
ethically acceptable to those who would take part in it?
2. Would a balanced placebo study of antidepressants be
pragmatic, i.e. would potential participants be prepared to
take part in such a study?
We also sought opinion as to whether it would make a dif-
ference to views on ethics and participation if subjects
were pre-consented, or if deception were minimised.
Methods
We sought opinions on the ethics and pragmatics of intro-
ducing an element of deception into antidepressant drug
trials from members of the following groups of people liv-
ing or working within the city of Liverpool:
1. General practitioners (GPs).
2. Psychiatrists.
3. People diagnosed with at least one episode of depres-
sion.
Identification and recruitment
The names and contact details of all GPs and psychiatrists
registered as working within Liverpool were identified
through Liverpool Primary Care Trusts and Mersey Care
NHS Trust. In order to minimize bias GPs and psychia-BMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
Page 5 of 12
(page number not for citation purposes)
trists with a particular interest in the subject, or knowledge
of members of the study team, were excluded from the
study. 250 GPs were eligible for inclusion in the study.
125 of these GP's were randomly selected to be included
in the study. The list of eligible GPs were arranged alpha-
betically and assigned numbers from 1 to 250. A physical
random number generator (based on optical quantum
physics) was employed. Duplications were permitted so
that the probability of GPs being selected remained con-
stant. All 65 eligible psychiatrists were selected for inclu-
sion in the study.
Those selected were contacted by letter with an invitation
to take part. These people were then contacted by tele-
phone two weeks after receiving the letter, to discuss par-
ticipation in the study. Those responding positively were
given a participant information sheet and invited to com-
plete the participant consent form. Those who agreed
were asked to complete a brief questionnaire, indicating
amongst other things, their length of time in practice, the
extent of their involvement with mental health work, and
their views on the efficacy of antidepressant medication.
Purposive samples for interview were then created, based
on the screening questionnaire responses. The main crite-
rion for selection was to obtain a sample which reflected
a range of opinion about antidepressant medication. We
also took account of estimated proportion of patients'
depressed [GP's only], special role in research, special role
in mental health [GP's only], gender, number of GP part-
ners [GP's only] and time since completion of training,
when determining the precise composition of the inter-
view sample.
People with at least one diagnosed episode of depression
were identified through the practice records of those GPs
who agreed to participate in the study. GPs wrote to suit-
able patients about the study and invited them to contact
the research team. Those patients who did so were fol-
lowed up by JGH. JGH arranged to meet them to discuss
any concerns they might have, give them the participant
information sheet and study consent form, and invite
those who consented to the study to complete a brief
questionnaire. This included questions on current mental
state, opinion towards antidepressant medication, and
age, gender and educational level.
Data gathering
Focus groups were the data-gathering method of choice.
This type of abstract and conceptual issue is often well
suited to focus groups as the interaction helps people to
explore and refine their own perspectives, attitudes and
beliefs.
In-depth interviews
It was envisaged in designing the study that some partici-
pants might not be willing or able to join a group, or
might feel uncomfortable about talking openly in a
group. We therefore offered in-depth individual inter-
views as an alternative to participation in a focus group.
The focus groups and interviews sought the opinions of
participants on the acceptability and feasibility of intro-
ducing an element of temporary deception into antide-
pressant drug trials. The participants were briefed in the
invitation letter and in the introduction to the interview
or focus group on the issues to be discussed (see Acknowl-
edgements). A vignette-based topic guide invited partici-
pants' views on three different strategies for deception:
post-hoc, authorised, and minimised deception (See
Vignettes 1–3).
Vignette1: Post-hoc deception
Peter is feeling miserable and out of sorts, and decides to go
and see his family doctor. Peter and his doctor agree that he
is suffering from depression, and that antidepressant medi-
cation might be a helpful treatment for him. Peter is then
invited to take part in a trial, and is told that he will receive
either an antidepressant or a placebo. He will be told which
one he is taking. Peter agrees to take part. After the trial is
over, Peter is told that he had not, after all, been fully
informed about what happened. Half of the people who
were told they were given the antidepressant medication,
were in fact given the placebo. And half of the people who
were told they were given the placebo, were in fact given the
antidepressant.
Vignette 2: Authorised deception
First, imagine the same scenario as before. This time, how-
ever, you are told in advance that there will be an element
of temporary deception in the trial. You are not told exactly
what that element will be. You will be given a sheet of paper
something like this: "You should be aware that the investi-
gators have intentionally misdescribed certain aspects of
this study. This use of deception is necessary to conduct the
study. However, an independent ethics panel has deter-
mined that this form accurately describes the major risks
and benefits of the study. The investigators will explain the
misdescribed aspects of the study to you at the end of your
participation".
Vignette 3: Minimised deception
Imagine that you go to see your doctor when you are feeling
depressed, as before. You agree to take part in an antide-
pressant drug trial. This time you are told either, 'you will
probably receive 'placebo', or, you will probably receive an
antidepressant'. You agree to take part.BMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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After the trial is over, this is what you find out. One third
of the people who were told they were given the antidepres-
sant medication, were in fact given the placebo. And one
third of the people who were told they were given the pla-
cebo, were in fact given the antidepressant. This is set out
in Table 1. Since you had been told that you would proba-
bly get either antidepressant or placebo, there was not –
technically – any deception involved in this trial.
Ethical approval for the study was granted by Liverpool
Paediatric Research Ethics Committee (reference 04/
Q1502/83).
Analysis
All interviews and focus groups were audio-taped and
transcribed verbatim. Transcripts were analysed themati-
cally using Framework, a manual, matrix method, which
facilitates thematic and cross-case interpretation [17,18].
Analysis proceeded in five stages:
￿ Familiarization. Transcripts were read and re-read by all
the research team to familiarize and immerse in the data.
￿ Identification of the thematic framework. Meetings were
held with the whole research team to discuss and identify
Key issues, concepts and themes arising from the data, and
to group them thematically to construct a conceptual
framework.
￿ Indexing. Two of the research team (JGH and JJH) inde-
pendently applied the thematic framework to the same
transcript to explore any differences in application. The
thematic framework was then applied systematically to all
the data by JGH. The point of saturation of themes (i.e. no
new themes emerging from new data coded) was reached
before the end of the coding of the data set.
￿ Charting. JGH constructed thematic matrices for all
identified categories/subcategories to further summarise
and synthesise the indexed data. One of the transcripts
was also independently charted by JJH to explore any dif-
ferences in charting.
￿ Detection, categorization and classification. The original
research questions were reconsidered by the research
team, and the charts examined in order to define con-
cepts, map the range and nature of phenomena, find any
associations and provide explanations.
Results
Samples
Twenty seven general practitioners, 15 psychiatrists and
six patients with experience of depression agreed to take
part in the study and completed screening questionnaires.
Two focus groups and two in-depth interviews were con-
ducted with a total of 14 GPs, of whom six were female.
They reported a wide range of experience in general prac-
tice, and of expertise in mental health and research. Thir-
teen GPs considered antidepressants to be probably
helpful in treating depression, the other was uncertain.
One focus group and five in-depth interviews were con-
ducted with a total of eight psychiatrists, of whom four
were female. Five were consultant psychiatrists, while
three were specialist registrars. Two psychiatrists felt anti-
depressants were necessary in the treatment of depression,
four that they were probably helpful, with two indicating
they were unsure whether antidepressants were helpful.
Five interviews were conducted with patients, of whom
three were female. Their age range was 37–50, and all but
one had received more than two years education since age
16. All had experience of taking antidepressants, with
three reporting themselves as currently depressed. Four
patients perceived antidepressants as probably helpful,
while one saw them as necessary in treating depression.
Further information on the numbers of participants tak-
ing part in focus groups or individual interviews is given
in Table 2 and a summary of the key characteristics of the
study sample is given in Table 3.
Participants' views on deception in clinical trials
Many participants accepted the need to consider alterna-
tive approaches to research into antidepressants. Based on
participants' prior knowledge and experience, concerns
were expressed at the lack of an evidence base to support
the prescribing of antidepressant medication, particularly
for mild or moderate depression. There was a desire for
research to be conducted which more accurately reveals
the pharmacological effect of antidepressants:
"I mean is the medical professional deceiving itself at the
moment in terms of its belief that antidepressants
work?...Are we all being hoodwinked at the moment in
terms of the fact that we believe that antidepressants work
and they don't?" GP 10
Participants generally did not view deception as being
intrinsically unacceptable. They spoke about "acts of
omission" and being "economical with the truth" in clin-
ical practice, and the "little white lies" in everyday life.
Only one, a psychiatrist, saw it as intrinsically unethical to
introduce deception into any research setting. All partici-
pants could see the potential utility of introducing decep-
tion into trial designs.
However views on the ethical acceptability of deception
within antidepressant drug trials varied significantly, andBMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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no consensus was found on any of the presented strate-
gies.
Post-hoc deception, where participants are informed that
the clinical trial involved an element of deception only
after the completion of the trial, was considered unaccept-
able by the overwhelming majority of participants. Objec-
tions were predominantly based on concerns for the
welfare of patients taking part in post-hoc deceptive trials,
and a perceived moral and legal obligation for researchers
to obtain valid informed consent.
"I think as soon as you go into outright lies, as soon as that
becomes the practice of the study you're crossing a line, and
I think, I think ethically it's probably unacceptable."
Patient 02
Authorised deception, where participants give prior consent
to take part in a trial which involves an element of decep-
tion, was the most commonly accepted strategy. However
some participants argued that this strategy would reduce
the pragmatic effectiveness of the study because partici-
pants may correctly deduce the element of deception: and
hence that, if an authorised deceptive trial where unlikely
to generate valid findings, it should not be conducted.
"I think, you know, if you consent people to deception then
ethically I haven't got a problem with it. But I can't see the
point because you might as well just do a placebo controlled
trial" GP 08
Minimised deception, involving the use of ambiguous lan-
guage to mislead participants on the probability of being
assigned to treatment arms, was considered acceptable by
many participants. However, with minimised deception
the "devil's in the detail", with acceptability being inextri-
cably linked to the precise wording of the information
provided to potential participants, and the statistical
probability of participants being assigned to the various
treatment arms.
"The devil's in the detail and the wording is all important.
And it has to convey a reasonably accurate analysis of the
situation, whilst ... trying to eradicate the placebo effect as
much as possible."
Patient 02
When asked whether they would likely be willing to par-
ticipate in a deceptive trial of antidepressants opinion var-
ied considerably. One patient, two GPs and three
psychiatrists indicated that they would be unlikely to
recruit for, or participate in, any of the presented strategies
for deceptive trials. With one psychiatrist and two patients
stating that they would be likely to participate in any of
the deceptive trials presented, and were the only partici-
pants who indicated they would participate in a post hoc
deceptive trial of antidepressants. For these three partici-
pants the main motivational factor was a desire to further
knowledge of antidepressant efficacy, and the opportunity
to contribute to improvements in the treatment of other
patients with depression.
"I think I'd do anything to help researchers really.... I would
try all three. If I can't recruit I can't, but I wouldn't say no."
Psychiatrist 04
However the patients indicated that their participation
would likely be dependent on their condition at that
point in time, with them being more amenable to partici-
pation if their condition was currently impacting on their
quality of life. and certain trial practicalities, such as the
monitoring procedures. The hope of gaining alleviation
from their depressive symptoms was also found to be a
factor in their willingness to participate in any trial.
Table 1: to be inserted into vignette 3
'You will probably get a placebo' 'You will probably get an antidepressant'
Given placebo 67% 33%
Given drug 33% 67%
Table 2: Study sample by data gathering method
GPs Psychiatrists Patients
Focus groups 12 (7,5)* 3 0
Interviews 2 5 5
TOTAL 14 8 5
* Brackets indicate: focus group 1 = 7 participants, focus group 2 = 5 participantsBMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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"I think I'd take part in all of them..... I think from my
point of view, if I felt I still had elements of a depressive ill-
ness and I was still being held back in a way, by the symp-
toms of depressive illness, I would take part in the survey,
hypothetically as you say. If I felt that I'd reached a stage
with my depression that it was no longer a factor in a) my
working life, b) my social life, c) my domestic life, then I
wouldn't, because you're on the straight and narrow and
you don't want anything to demur from that or jeopardise
it. But if, you know, I think you know with depression you
have a feeling of dissatisfaction with the condition. And if
the condition is still such that you're dissatisfied with it and
you feel there are still elements of it that are affecting you,
then yes, hypothetically." Patient 02.
"I think my reaction is such well because you know how
horrible the situation can be, if you are doing something
which can actually perhaps alleviate that horror, well then
why not, its not going to harm me, so I think yes I probably
would." Patient 06
Of those who would agree to participate in a deceptive
trial, the authorised deceptive design was the trial strategy
which GP's and psychiatrists indicated they would be
most willing to recruit for. In contrast the deceptive trial
design which patients were most likely to agree to partici-
pate in was the minimised deceptive trial, with all five
patients indicating that they would likely participate in
such a trial.
Table 3: Study sample (focus groups and interviews)
GPs Psychiatrists Patients
Gender:
Male 8 4 2
F e m a l e 643
Views on antidepressants
Necessary 0 2 1
Probably helpful 13 4 4
N o t  s u r e 120
Probably unhelpful 0 0 0
Unhelpful 0 0 0
Patients:
Currently depressed 3
Not currently depressed 2
Used anti-depressants 5
Never used a-d* 0
<2 yrs post-16 educ 4
>2 yrs post-16 educ 1
Psyciatrists:
Consultant 5
Registrar 3
Consultant for <5 yrs 2
Consultant 5–20 yrs 3
Consultant >20 yrs 0
GPs:
Special role in mh** 4
No special role in mh 10
Special role in research 4
No special role in res. 10
Qualified for <5 yrs 0
Qualified 5–20 yrs 6
Qualified >20 yrs 8
proportion of their patients 
perceived as being depressed:
<10% 2
10–30% 9
>30% 3
* anti-depressants, **mental healthBMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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Factors influencing participants' views
The major issues that affected participants' views about
the acceptability of deception studies were
￿ the welfare and capacity of patients
￿ practicalities of trial design
￿ the question of trust
￿ benefits.
Welfare and capacity
Participants from all of our samples (GPs, psychiatrists
and patients) were concerned about the welfare of patients
participating in deceptive trials. These included risks to
patients from not receiving antidepressants, increased
risks to patients if doctors were also deceived about their
patient's treatment, and the need to ensure adequate
monitoring processes and means of removing those
patients whose condition deteriorates:
"...if they were doing weekly Beck scores or something, I
suppose that, and asked directly you know, how are you feel-
ing, are you happy with your medication, and you know
some check of their mood and their safety. Then maybe,
yeah maybe this could be acceptable actually this decep-
tion." Psychiatrist 07, discussing post-hoc deception.
The  capacity  of patients with depression, particularly
severe or longstanding depression, to provide valid
informed consent was a cause for concern. Participants
considered that the complex nature of authorised or min-
imised deception would make it more difficult than usual
to obtain valid informed consent:
"I mean, the issue is if a person is really truly depressed, to
what extent is he truly autonomous? To what extent is he or
she in a position to make a decision, you know, in terms of
giving their consent to a trial with all the informed infor-
mation that goes with it?" GP21
Practicalities
There was considerable discussion about practicalities,
about the specific aspects of trial characteristics which
might make any deceptive trial more, or less, acceptable.
There was general agreement that, in addition to detailed
consent procedures and clear methods for monitoring
patients, acceptability would be enhanced if the trial were
brief, and the post-trial disclosure of high quality:
"I think the full disclosure of information at the end would
go some way to persuade you in like your feelings about the
wrongness of the deception. " Patient 01
"But a timescale would be important. So they could say,
"yeah I can go with this for a couple of weeks but I wouldn't
be able to go with it for two months," for instance. So the
problem with the antidepressants is the kick in time varies
but it's going to take quite a long time, so to me one of the
relevant bits of this would be how long you would be deceiv-
ing them for." GP 22
Some participants thought that the opinions and endorse-
ment of valued individuals and organisations, including
the responsible doctor, would help to reassure them
about the acceptability of deception within trials:
"I know things are hard to get through ethics committees
and panels so it would, it would give me confidence in that
way, that it has been like properly determined and every-
thing, it's not just somebody coming up with the idea of I'm
going to go out and do this. But its about hmm, see I would
discuss it with my GP and see what they felt, and not saying
I would be totally swayed by them but I would want, be
interested in their opinion." Patient 03
Trust
The question of trust was critical, and contentious, partic-
ularly with regard to the post-hoc deception scenarios.
Many participants considered trust, whether in the
research process or the doctor-patient relationship, to be
of paramount importance.
"I personally would be feeling really fucking pissed off if, to
discover afterwards that I thought I was being told the
truth. Because part of taking part in a trial involves a degree
of trust in the people who are conducting it." GP 09 (refer-
ring to reaction to participating in a post-hoc decep-
tive trial).
"I don't think it can be justified by the greater good, you
know because I think it's such a serious undermining of
trust that there is no greater good in terms of slightly
improved survey results or whatever, I think the greater
good lies with the trust and not breaking that." Patient 02
(discussing post-hoc deception).
"The whole basis on which we operate is that people trust us
to have their best intentions at heart and if we are part of
deliberately deceiving them, where does that end. You can't
say, I know I lied to you about this trial but I'll be honest
about your mum or your kids or your own health. It doesn't
work, once it's contaminated its contaminated." GP 12
There were mixed views as to whether or not trust between
doctor and patient would be adversely affected if the doc-
tor, as well as the patient, were blinded to the deception.
GPs and psychiatrists were more likely to prefer to be
blinded, because they felt this would preserve their rela-BMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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tionship with their patients and absolve themselves from
blame in the patients' eyes.
"I would feel more comfortable as a GP, with a GP hat on,
if I didn't know that the patient [was being
deceived],because I would feel that I'm more truthful, hon-
est with the patient, rather than, what would I have to be,
dishonest. Doctor patient relationship would be put at risk,
I feel. I would be much happier if I wasn't informed." GP
23
Patients, by contrast, were inclined to prefer their doctors
to be 'in on' the deception, based on a belief in protective
power of physicians' knowledge, and would tend to still
hold the doctor culpable.
"Well it's still coming from somewhere isn't it and well that
shouldn't be allowed anyway, because it's just coming from,
it's got to come from somewhere in the beginning. So we
have put our trust in the GP, they should be know-
ing.....They should know. So they should be telling us."
Patient 04
There were also concerns about the consequences for trust
in future research, if precedents for deception were to be
set. Would studies like this be the beginning of a slippery
slope?
"The worry at another level it is sort of then where do we
stop? I mean we have these ethical discussions about so
many issues now, treatment and this, that, and all the rest
of that, so where do we, where does the deception stop then?
This study could lead to another study where it involved
deception, and the deception could be at a higher level, and
involve more and more risk. And then if you set a precedent
and do this study, then of course people will go to that prec-
edent and say that got approved and we could do this one
as well." PSY06
Benefits
A minority of participants thought that the balance of
risks and benefits could be in favour of deception trials:
that the greater good for patients in general from such
studies could outweigh the potential for harm to an indi-
vidual patient, or to their relationship with their doctor.
"I wouldn't be cross at all if that happened, because I know,
in a kind of the ins and outs of what happens in research
and why it should happen. So if I've agreed then I wouldn't
worry about anything else after." Psychiatrist 04 (refer-
ring to perspective of a patient taking part in a post-
hoc deceptive trial of antidepressants)
"If we don't do research like this that involves doing some-
thing and deceiving the patient, there is a risk that you will
harm other patients, and part of the ethical dilemma, I
think, is in deciding whereabouts your tipping point is." GP
14
Discussion
This study is the first to ask those people who would be
likely to be invited to take part in an antidepressant drug
trial involving elements of deception, about their views of
the ethical and practical issues involved in conducting
such a trial. General practitioners, psychiatrists and
patients with experience of depression are the three
groups of people who most commonly take part in anti-
depressant drug trials. Their opinions are therefore critical
in determining whether balanced placebo designs have a
viable future in antidepressant drug trials.
Our techniques for recruitment and sampling were
designed to generate as wide a range of opinion as possi-
ble. We noted that the majority of participants from all
three groups considered antidepressant medication to be
probably helpful, with only three participants expressing
uncertainty about their efficacy. All patient participants
had experience of antidepressant medication, though not
all had found it personally effective. We think it probable
that this range of views represents the diversity of opinion
of both the professional groups involved in our study, and
of those patients with experience of depression who
decide to engage with primary healthcare. However biases
are possible, with regard to the specificity of the locality
and the likelihood that those who agreed to take part had
a particular interest in the subject. We recruited fewer
patients than anticipated, in part because of the con-
straints of having to go through the general practitioner. It
is possible that those patients selected by their general
practitioner were chosen on the basis of having a story to
tell, or because their views were likely to be congruent
with those of their doctor.
Many of the issues raised by the participants in this study
apply to all randomised controlled trials, not just to those
potentially involving deception. We accept, however, that
the complexity of study designs involving balanced pla-
cebo options makes informed consent even more difficult
to obtain than in conventional trials. We consider that
this may pose particular problems with trials involving
depressed people, given concerns about reduced mental
capacity.
The underlying problem with authorised deception iden-
tified by our participants – that participants may correctly
guess the deceptive element of the trial – has also been
acknowledged by Miller et al [19]. To date this has only
been formally tested in trials involving psychology stu-
dents. It will be important to consider the extent to whichBMC Health Services Research 2007, 7:64 http://www.biomedcentral.com/1472-6963/7/64
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this problem applies with other subjects and in other set-
tings.
Alternative trial designs can be considered. One option,
used successfully by Colloca and colleagues in an analge-
sia trial, is to adopt a combination of placebo run-ins and
informed consent [20]. In this design all study partici-
pants are informed that they will start with a placebo.
They are told that an active drug may be substituted after
a while; and that they may (or may not) be informed
when this switch is made. This protocol gives evidence for
three of the four arms of a classic balanced placebo design
– excluding 'told drug/no drug' – without any element of
deception.
Conclusion
There are legitimate concerns about the designs of current
randomised placebo controlled trials of antidepressant
medication, and the consequent limited validity of evi-
dence arising from such trials.
Balanced placebo designs may be theoretically useful to
address current design flaws. However, bringing decep-
tion into trials of antidepressant medication is both ethi-
cally and practically problematic. There is a trade-off
between pragmatic and ethical responses to the question
of whether, and under what circumstances, elements of
deception could be introduced into antidepressant drug
trials. Ensuring adequate ethical safeguards within bal-
anced placebo designs is likely to diminish their ability to
address the crucial issue of additivity. Participants in our
study, who were deliberately recruited from those groups
of doctors and patients likely to take part in any such trial
in the future, could see substantial inherent problems
with all proposed options for studies which included ele-
ments of deception.
Our conclusion, therefore, is that the balanced placebo
designs considered in this study may not be feasible for
introduction into future trials of antidepressant medica-
tion.
Given that the evidence-base for current antidepressant
prescribing practices is equivocal, there remains an urgent
need for improvement in trial design. This is necessary if
we are to improve the quality of evidence about the utility
and limitations of antidepressant medication, and the sig-
nificance or otherwise of associated placebo characteris-
tics, in order to help patients in distress and doctors in
routine clinical practice. Alternative study designs, includ-
ing placebo run-ins with informed consent, offer poten-
tial benefits. There may also be valuable lessons to be
learned from a systematic re-examination of a range of
placebo or contextual characteristics reported in previ-
ously published studies.
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